Company intelligence / Profile preview

Sichuan Yuanshengtai Biotechnology

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Sichuan Yuanshengtai Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the research and development of innovative small molecule therapeutics. The company's primary focus lies in oncology and metabolic diseases, where it seeks to develop targeted therapies with improved safety and efficacy profiles. Its lead clinical asset, YST-001, is a multi-target tyrosine kinase inhibitor currently being evaluated in Phase 1 trials for patients with advanced solid tumors. Yuanshengtai operates out of the Chengdu Medical City, utilizing its integrated R&D platform to advance its early-stage pipeline.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sichuan Yuanshengtai Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Yuanshengtai Biotechnology.

Explore the full profile